Carbaglu® (carglumic acid)
Orphan Europe was founded in 1990 to provide treatments for people with a rare disease. Orphan Europe was acquired by Recordati in 2007. Recordati is an international pharmaceutical company listed on the Italian stock exchange and has over 3,300 staff dedicated to the research, development, manufacturing and marketing of pharmaceuticals. An orphan drug is a medicinal product developed for the treatment of a rare disease. In Europe, a rare disease is defined as a condition that affects less than 5 per 10, 000 inhabitants, and is fatal or severely debilitating. There are over 7,000 known rare diseases, which means that several million people are affected all over the world – over 25 million in Europe alone. Today, treatment exists for only 200–300 diseases. Rare diseases are often genetic, meaning that newborns, children, and young adults often are affected. Physicians may never see a patient with a rare disease. For that reason there’s always a risk that when a baby is born with a rare disease, a correct diagnosis may not be made and appropriate treatment may not be given.